Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Advances in antibody-drug conjugates for breast cancer at ESMO 2022

Naoto Ueno • 10 Sep 2022
ESMO 2022
Breast Cancer Antibodies Sacituzumab govitecan Trastuzumab deruxtecan
DESTINY-Breast04 TROPiCS-02

Naoto Ueno, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses updates from TROPiCS-2 (NCT03901339) and DESTINY-Breast04 (NCT03734029), which both investigated antibody-drug conjugates for patients with breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoto Ueno

1:45
Targeting EGFR for the treatment of inflammatory breast cancer
Naoto Ueno • 11 Sep 2022
0:52
Defining HER2-low breast cancer as a clinical subtype
Naoto Ueno • 10 Sep 2022
2:30
Patient-reported outcomes from DESTINY-Breast04
Naoto Ueno • 10 Sep 2022

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals